HRP20100354T1 - Nova formulacija tumoru pridruženih peptida koji se vežu na antigene humanih leukocita (hla) razreda i i ii za uporabu u cjepivima - Google Patents
Nova formulacija tumoru pridruženih peptida koji se vežu na antigene humanih leukocita (hla) razreda i i ii za uporabu u cjepivima Download PDFInfo
- Publication number
- HRP20100354T1 HRP20100354T1 HR20100354T HRP20100354T HRP20100354T1 HR P20100354 T1 HRP20100354 T1 HR P20100354T1 HR 20100354 T HR20100354 T HR 20100354T HR P20100354 T HRP20100354 T HR P20100354T HR P20100354 T1 HRP20100354 T1 HR P20100354T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- peptides
- pharmaceutical composition
- peptide
- composition according
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 30
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 19
- 239000000203 mixture Substances 0.000 title claims abstract 8
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 6
- 238000009472 formulation Methods 0.000 title claims 2
- 229960005486 vaccine Drugs 0.000 title claims 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 210000000265 leukocyte Anatomy 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 13
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract 7
- 229930195725 Mannitol Natural products 0.000 claims abstract 7
- 235000010355 mannitol Nutrition 0.000 claims abstract 7
- 239000000594 mannitol Substances 0.000 claims abstract 7
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims abstract 5
- 229920001993 poloxamer 188 Polymers 0.000 claims abstract 5
- 229940044519 poloxamer 188 Drugs 0.000 claims abstract 5
- 150000001413 amino acids Chemical class 0.000 claims abstract 4
- 229920001184 polypeptide Polymers 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08008292A EP2113253B1 (fr) | 2008-04-30 | 2008-04-30 | Nouvelles formules de peptides associées aux tumeurs à liaison aux molécules II ou I de classe d'antigène (HLA) de leucocyte humain pour vaccins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100354T1 true HRP20100354T1 (hr) | 2010-07-31 |
Family
ID=39643855
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100354T HRP20100354T1 (hr) | 2008-04-30 | 2010-06-28 | Nova formulacija tumoru pridruženih peptida koji se vežu na antigene humanih leukocita (hla) razreda i i ii za uporabu u cjepivima |
| HR20110965T HRP20110965T1 (hr) | 2008-04-24 | 2011-12-21 | Nove formulacije peptida povezanih s tumorima koji se vežu za molekule ljudskog leukocitnog antigena (hla) klase i ili ii za cjepiva |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110965T HRP20110965T1 (hr) | 2008-04-24 | 2011-12-21 | Nove formulacije peptida povezanih s tumorima koji se vežu za molekule ljudskog leukocitnog antigena (hla) klase i ili ii za cjepiva |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9289478B2 (fr) |
| EP (2) | EP2113253B1 (fr) |
| JP (1) | JP5717268B2 (fr) |
| CN (1) | CN105749285A (fr) |
| AT (2) | ATE462442T1 (fr) |
| AU (1) | AU2009201589C1 (fr) |
| BR (1) | BRPI0900798A8 (fr) |
| CA (1) | CA2665510C (fr) |
| CY (1) | CY1110178T1 (fr) |
| DE (1) | DE602008000891D1 (fr) |
| DK (2) | DK2113253T3 (fr) |
| EA (1) | EA017492B1 (fr) |
| ES (2) | ES2342506T3 (fr) |
| HR (2) | HRP20100354T1 (fr) |
| MX (1) | MX2009004468A (fr) |
| NZ (1) | NZ576423A (fr) |
| PL (2) | PL2113253T3 (fr) |
| PT (2) | PT2113253E (fr) |
| RS (1) | RS52115B (fr) |
| SI (2) | SI2113253T1 (fr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
| WO2006023598A2 (fr) | 2004-08-19 | 2006-03-02 | University Of Maryland, Baltimore | Peptides restreints par mhc classe ii derives d'antigenes specifiques a la prostate et leur utilisation dans des vaccins destines a traiter ou a prevenir le cancer de la prostate |
| CA2694805C (fr) | 2007-07-27 | 2014-09-09 | Immatics Biotechnologies Gmbh | Nouveaux epitopes immunogenes destines a l'immunotherapie |
| PT2660248E (pt) | 2007-07-27 | 2015-10-12 | Immatics Biotechnologies Gmbh | Nova imunoterapia para tumores neuronais e cerebrais |
| CY1112212T1 (el) * | 2008-04-24 | 2015-12-09 | Immatics Biotechnologies Gmbh | Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια |
| NO2119726T3 (fr) | 2008-05-14 | 2015-05-23 | ||
| AU2009288289B2 (en) * | 2008-08-25 | 2012-11-08 | Amplimmune, Inc. | PD-1 antagonists and methods of use thereof |
| CA2734908A1 (fr) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions d'antagonistes de pd-1 et methodes d'utilisation associees |
| AU2016204712B2 (en) * | 2008-10-01 | 2018-03-01 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
| PT2172211E (pt) * | 2008-10-01 | 2015-03-09 | Immatics Biotechnologies Gmbh | Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer |
| AU2014271235B2 (en) * | 2008-10-01 | 2017-03-02 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201019331D0 (en) | 2010-03-19 | 2010-12-29 | Immatics Biotechnologies Gmbh | Methods for the diagnosis and treatment of cancer based on AVL9 |
| GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| AU2015200751B2 (en) * | 2010-03-19 | 2016-11-10 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| KR20130126671A (ko) * | 2010-12-14 | 2013-11-20 | 이매틱스 바이오테크놀로지스 게엠베하 | 전립선 관련 항원 분자로부터 유래된 hla 결합 펩티드 및 이의 사용방법 |
| WO2013041542A1 (fr) * | 2011-09-19 | 2013-03-28 | Alf Lamprecht | Formulations pharmaceutiques comprenant des sphérolyophilisats de molécules biologiques |
| WO2013133405A1 (fr) | 2012-03-09 | 2013-09-12 | オンコセラピー・サイエンス株式会社 | Composition pharmaceutique contenant un peptide |
| EP3597178A1 (fr) * | 2012-06-21 | 2020-01-22 | Phosphorex Inc. | Nanoparticules d'indirubine, leurs dérivés et leurs procédés de fabrication et d'utilisation associés |
| TWI777194B (zh) | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（一） |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| CA2984643A1 (fr) | 2015-05-13 | 2016-11-17 | Agenus Inc. | Vaccins pour le traitement et la prevention du cancer |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| EA201792531A1 (ru) * | 2015-06-19 | 2018-05-31 | Имматикс Байотекнолоджиз Гмбх | Новые пептиды и комбинации пептидов для применения в иммунотерапии и способы получения каркасов для применения при лечении рака поджелудочной железы и других видов рака |
| US9895446B2 (en) | 2015-07-14 | 2018-02-20 | Professional Compounding Centers Of America | Poloxamer-based intralesional injections for the delivery of chemotherapeutic agents |
| TWI765875B (zh) | 2015-12-16 | 2022-06-01 | 美商磨石生物公司 | 新抗原辨識、製造及用途 |
| MA47367B1 (fr) * | 2017-01-27 | 2023-06-28 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
| AR110857A1 (es) | 2017-01-27 | 2019-05-08 | Immatics Biotechnologies Gmbh | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer |
| SG11201906198PA (en) * | 2017-01-27 | 2019-08-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| EP3694532A4 (fr) | 2017-10-10 | 2021-07-14 | Gritstone Oncology, Inc. | Identification de néo-antigènes au moyen de points chauds |
| JP2021503897A (ja) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のためのジャンクションエピトープ提示の低減 |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| CA3096909A1 (fr) | 2018-04-26 | 2019-10-31 | Agenus Inc. | Compositions peptidiques de liaison a une proteine de choc thermique (hsp) et leurs methodes d'utilisation |
| FR3087448B1 (fr) | 2018-10-23 | 2023-10-13 | Pdc Line Pharma | Lignee pdc modifiee pour secreter une cytokine |
| JP2023526228A (ja) * | 2020-05-12 | 2023-06-21 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 膠芽腫を処置するための方法 |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102020125465A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| WO2023148333A1 (fr) | 2022-02-03 | 2023-08-10 | CeCaVa GmbH & Co. KG | Co-vaccination avec des antigènes cd4 et cd8 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6045796A (en) * | 1992-12-17 | 2000-04-04 | Anergen, Inc. | Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| CN1151842C (zh) * | 1995-07-27 | 2004-06-02 | 基因技术股份有限公司 | 稳定等渗的冻干蛋白制剂 |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US5861483A (en) * | 1996-04-03 | 1999-01-19 | Pro-Neuron, Inc. | Inhibitor of stem cell proliferation and uses thereof |
| US20030162711A1 (en) * | 1996-04-24 | 2003-08-28 | Soren Bjorn | Pharmaceutical formulation |
| US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| DE19917195B4 (de) | 1999-04-16 | 2006-09-28 | Immatics Biotechnologies Gmbh | Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor |
| WO2001029220A2 (fr) * | 1999-10-19 | 2001-04-26 | Ludwig Institute For Cancer Research | Peptides antigeniques mage-a12 et utilisation |
| US6897288B1 (en) * | 1999-10-19 | 2005-05-24 | Ludwig Institute For Cancer Research | Mage-A12 antigenic peptides and uses thereof |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| CN101912601B (zh) * | 2002-06-21 | 2012-08-29 | 诺和诺德医疗保健公司 | 因子vii多肽的稳定化固体组合物 |
| EP2181595A1 (fr) * | 2002-08-16 | 2010-05-05 | Yeda Research And Development Company Ltd. | Antigène spécifique de tumeurs, peptides associés et utilisation de ceux-ci en tant que vaccins antitumoraux |
| AU2004229458B2 (en) * | 2003-04-11 | 2009-11-19 | Antigenics, Inc. | Improved heat shock protein-based vaccines and immunotherapies |
| TW200539855A (en) * | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| DE102004026135A1 (de) * | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| CN101056650A (zh) * | 2004-11-12 | 2007-10-17 | 诺和诺德公司 | 促胰岛素肽的稳定制剂 |
| EP1674082A1 (fr) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Procédé pour la manufacture des suspensions ou lyophilisates steriles des complexes mal-soluble de peptides basic, des formulations pharmaceutiques avec ces complexes et leur utilisation comme medicament |
| ATE512160T1 (de) * | 2005-04-26 | 2011-06-15 | Immatics Biotechnologies Gmbh | T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen |
| ATE440107T1 (de) | 2005-09-05 | 2009-09-15 | Immatics Biotechnologies Gmbh | Tumorassoziierte peptide, die hla klasse i oder ii-moleküle binden, und anti-tumor impfstoffe |
| PT1806358E (pt) * | 2005-09-05 | 2010-05-28 | Immatics Biotechnologies Gmbh | Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii |
| WO2007028753A2 (fr) | 2005-09-09 | 2007-03-15 | Basf Aktiengesellschaft | Melanges fongicides a base de triazoles |
| WO2007146668A2 (fr) * | 2006-06-06 | 2007-12-21 | University Of Massachusetts | Utilisation d'imp3 en tant que marqueur pronostique de cancer |
| NO2119726T3 (fr) * | 2008-05-14 | 2015-05-23 | ||
| PT2172211E (pt) * | 2008-10-01 | 2015-03-09 | Immatics Biotechnologies Gmbh | Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer |
-
2008
- 2008-04-30 PT PT08008292T patent/PT2113253E/pt unknown
- 2008-04-30 AT AT08008292T patent/ATE462442T1/de active
- 2008-04-30 ES ES08008292T patent/ES2342506T3/es active Active
- 2008-04-30 PL PL08008292T patent/PL2113253T3/pl unknown
- 2008-04-30 EP EP08008292A patent/EP2113253B1/fr active Active
- 2008-04-30 DE DE602008000891T patent/DE602008000891D1/de active Active
- 2008-04-30 DK DK08008292.8T patent/DK2113253T3/da active
- 2008-04-30 SI SI200830038T patent/SI2113253T1/sl unknown
-
2009
- 2009-04-23 CN CN201610085112.0A patent/CN105749285A/zh active Pending
- 2009-04-23 JP JP2009104886A patent/JP5717268B2/ja active Active
- 2009-04-23 ES ES09005725T patent/ES2374138T3/es active Active
- 2009-04-23 AU AU2009201589A patent/AU2009201589C1/en not_active Ceased
- 2009-04-23 PL PL09005725T patent/PL2111867T3/pl unknown
- 2009-04-23 RS RS20110588A patent/RS52115B/en unknown
- 2009-04-23 SI SI200930119T patent/SI2111867T1/sl unknown
- 2009-04-23 US US12/428,893 patent/US9289478B2/en active Active
- 2009-04-23 DK DK09005725.8T patent/DK2111867T3/da active
- 2009-04-23 NZ NZ576423A patent/NZ576423A/en not_active IP Right Cessation
- 2009-04-23 AT AT09005725T patent/ATE526979T1/de active
- 2009-04-23 PT PT09005725T patent/PT2111867E/pt unknown
- 2009-04-23 EA EA200900487A patent/EA017492B1/ru not_active IP Right Cessation
- 2009-04-23 EP EP09005725A patent/EP2111867B1/fr active Active
- 2009-04-24 BR BRPI0900798A patent/BRPI0900798A8/pt not_active Application Discontinuation
- 2009-04-24 CA CA2665510A patent/CA2665510C/fr not_active Expired - Fee Related
- 2009-04-24 MX MX2009004468A patent/MX2009004468A/es active IP Right Grant
-
2010
- 2010-06-09 CY CY20101100508T patent/CY1110178T1/el unknown
- 2010-06-28 HR HR20100354T patent/HRP20100354T1/hr unknown
-
2011
- 2011-12-21 HR HR20110965T patent/HRP20110965T1/hr unknown
-
2012
- 2012-01-09 US US13/346,197 patent/US9283267B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100354T1 (hr) | Nova formulacija tumoru pridruženih peptida koji se vežu na antigene humanih leukocita (hla) razreda i i ii za uporabu u cjepivima | |
| ES2584430T3 (es) | Estrategias para prevenir y/o tratar las respuestas inmunitarias a los alofactores solubles | |
| HRP20150873T1 (hr) | Pripravci i postupci za lijeäśenje celijakije | |
| JP2008530975A5 (fr) | ||
| ES2343270T3 (es) | Vacunas contra el virus nipah. | |
| CY1107973T1 (el) | Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων | |
| HRP20170433T1 (hr) | Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci | |
| US9642895B2 (en) | Peptides for enhancing transdermal delivery | |
| EP2172212A3 (fr) | Composition de peptide associé aux tumeurs et vaccin anti-cancer associé pour le traitement de glioblastome (GBM) et autres cancers | |
| PL1794190T3 (pl) | Immunogenne epitopy komórek pomocniczych T pochodzące z ludzkich antygenów nowotworowych oraz sposoby stosowania tych epitopów w immunoterapii | |
| BRPI0815578B8 (pt) | peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina | |
| EP3058947A3 (fr) | Nouvelle immunothérapie contre plusieurs tumeurs y compris le cancer gastro-intestinal et le cancer gastrique | |
| WO2007048857A1 (fr) | Utilisation de peptides inhibiteurs du tgf-beta1 dans la preparation d'un agent modulateur de la reponse immunitaire | |
| JP2008543847A5 (fr) | ||
| EP2361930A3 (fr) | Multimeres du complexes peptide-cmh et leur utilisation dans des maladies infectieuses de borrelia | |
| JP7211938B2 (ja) | 免疫原性アルギナーゼペプチド | |
| BRPI0915696B8 (pt) | composição de vacina de rotavírus liofilizada e método de preparar a referida composição | |
| Attar et al. | Effect of two light-emitting diode (LED) and one halogen curing light on the microleakage of Class V flowable composite restorations | |
| JP2014502961A5 (fr) | ||
| JP2015533376A5 (fr) | ||
| RU2016116708A (ru) | Олигопептиды металлопротеиназ и их терапевтическое применение | |
| NZ594268A (en) | Grass peptides for vaccine | |
| BRPI0606614A2 (pt) | peptìdeos para distribuição de vacinas na mucosa | |
| BRPI0401908A (pt) | Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses | |
| RU2011150283A (ru) | Пептиды ттк и вакцины, их содержащие |